
eFFECTOR Therapeutics, Inc.
NASDAQ:EFTR
Overview | Financials
Company Name | eFFECTOR Therapeutics, Inc. |
Symbol | EFTR |
Currency | USD |
Price | 0.001 |
Market Cap | 2,823 |
Dividend Yield | 0% |
52-week-range | 0 - 16.882 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Stephen T. Worland Ph.D. |
Website | https://effector.com |
An error occurred while fetching data.
About eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD